EUPRAXIA PHARMACEUTICALS INC. (EPRX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05608681 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). PHASE2 Recruiting 117

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for EPRX.

SEC EDGAR Filings

All SEC filings for EUPRAXIA PHARMACEUTICALS INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.